Autologous control of a highly malignant syngeneic CRNK-16 leukemia in the rat: A role for NK cells

Cancer Immunology, Immunotherapy

Volumn 55, Issue 11, 2006, Pages 1348-1357

  Avraham, Roi ^a   Inbar, Shelly ^a   Rosenne, Ella ^a   Ben Eliyahu, Shamgar ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Leukemia; Natural killer cells; Rats; Tumor immunotherapy

Indexed keywords

INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD161; POLYINOSINIC POLYCYTIDYLIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CONTROL; CANCER SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE COURSE; GRAFT VERSUS LEUKEMIA EFFECT; HLA MATCHING; IMMUNE RESPONSE; IMMUNITY; LEUKEMIA; MALE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HLA ANTIGENS; IMMUNOTHERAPY; INTERLEUKIN-12; KILLER CELLS, NATURAL; LEUKEMIA; MALE; NEOPLASM METASTASIS; NEUTROPHILS; POLY I-C; RATS; RATS, INBRED F344; TIME FACTORS;

EID: 33746874801     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0139-5     Document Type: Article

References (46)

1. Lotzova E (1991) Natural killer cells: immunobiology and clinical prospects. Cancer Invest 9:173-184
2. Pross HF, Lotzova E (1993) Role of natural killer cells in cancer. Nat Immun 12:279-292
3. Moretta A, Moretta L (1997) HLA class I specific inhibitory receptors. Curr Opin Immunol 9:694-701
4. Moretta A, Biassoni R, Bottino C, Mingari MC, Moretta L (2000) Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol Today 21:228-34
5. Elkins WL, Pickard A, Pierson GR (1984) Deficient expression of class-I HLA in some cases of acute leukemia. Cancer Immunol Immunother 18:91-100
6. Leung W, Civin CI (2000) Use of purified stem and progenitor cells for transplantation. In: Atkinson EK (ed) Clinical bone marrow and blood stem cell transplantation. Cambridge University Press, Cambridge, pp 1191
7. Karre K (2002) Immunology. A perfect mismatch. Science 295:2029-2031
8. Lowdell MW, Craston R, Samuel D, Wood ME, O'Neill E, Saha V, Prentice HG (2002) Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol 117:821-827
9. Tajima F, Kawatani T, Endo A, Kawasaki H (1996) Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. Leukemia 10:478-482
10. Pawelec G, Da Silva P, Max H, Kalbacher H, Schmidt H, Bruserud O, Zugel U, Baier W, Rehbein A, Pohla H (1995) Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha. Leuk Lymphoma 18:471-478
11. Pierson BA, Miller JS (1996) CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood 88:2279-2287
12. Takahashi T, Hirano N, Chiba S, Yazaki Y, Hirai H (2000) Immunogene therapy against mouse leukemia using B7 molecules. Cancer Gene Ther 7:144-150
13. Rojas R, Roman J, Herrera C, Alvarez MA, Ramirez R, Torres A (2003) BALB/C mice injected with LSTRA leukemic cell line are cured by in vivo treatment with IL-2 + GM-CSF. Leuk Res 27:351-357
14. Zhang B, Wu KF, Lin YM, Ma XT, Rao Q, Zheng GG, Cao ZY, Li G, Song YH (2004) Gene transfer of pro-IL-18 and IL-1beta converting enzyme cDNA induces potent antitumor effects in L1210 cells. Leukemia 18:817-825
15. Saudemont A, Buffenoir G, Denys A, Desreumaux P, Jouy N, Hetuin D, Bauters F, Fenaux P, Quesnel B (2002) Gene transfer of CD154 and IL12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia. Leukemia 16:1637-1644
16. Reynolds CW, Bere EW Jr, Ward JM (1984) Natural killer activity in the rat. III. Characterization of transplantable large granular lymphocyte (LGL) leukemias in the F344 rat. J Immunol 132:534-540
17. Ward JM, Reynolds CW (1983) Large granular lymphocyte leukemia. A heterogeneous lymphocytic leukemia in F344 rats. Am J Pathol 111:1-10
18. Ryan JC, Niemi EC, Nakamura MC (2000) Functional analysis of natural killer cell receptors in the RNK-16 rat leukemic cell line. Methods Mol Biol 121:283-295
19. Leibson PJ (1997) Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity 6:655-661
20. Binstadt BA, Brumbaugh KM, Dick CJ, Scharenberg AM, Williams BL, Colonna M, Lanier LL, Kinet JP, Abraham RT, Leibson PJ (1996) Sequential involvement of Lck and SHP-1 with MHC-recognizing receptors on NK cells inhibits FcR-initiated tyrosine kinase activation. Immunity 5:629-638
21. Burshtyn DN, Scharenberg AM, Wagtmann N, Rajagopalan S, Berrada K, Yi T, Kinet JP, Long EO (1996) Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. Immunity 4:77-85
22. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413:732-738
23. Page GG, McDonald JS, Ben-Eliyahu S (1998) Pre-operative versus postoperative administration of morphine: impact on the neuroendocrine, behavioural, and metastatic-enhancing effects of surgery. Br J Anaesth 81:216-223
24. Chambers WH, Vujanovic NL, DeLeo AB, Olszowy MW, Herberman RB, Hiserodt JC (1989) Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells. J Exp Med 169:1373-1389
25. van den Brink MR, Hunt LE, Hiserodt JC (1991) In vivo treatment with monoclonal antibody 3.2.3 selectively eliminates natural killer cells in rats. J Exp Med 171:197-210
26. Fukumoto T, McMaster WR, Williams AF (1982) Mouse monoclonal antibodies against rat major histocompatibility antigens. Two Ia antigens and expression of Ia and class I antigens in rat thymus. Eur J Immunol 12:237-243
27. dim subpopulations of rat natural killer cells. J Immunol 148:3658-3665
28. Ben-Eliyahu S, Page GG (1992) In vivo assessment of natural killer cell activity in rats. Prog Neuroendocrineimmunol 5:199-214
29. Ben-Eliyahu S, Page GG, Yirmiya R, Taylor AN (1996) Acute alcohol intoxication suppresses natural killer cell activity and promotes tumor metastasis. Nat Med 2:457-460
30. Rook AH, Wood GS, Yoo EK, Elenitsas R, Kao DM, Sherman ML, Witmer WK, Rockwell KA, Shane RB, Lessin SR, Vonderheid EC (1999) Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 94:902-908
31. Smyth MJ, Taniguchi M, Street SE (2000) The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol 165:2665-2670
32. van Herpen CM, van der Laak JA, de Vries IJ, van Krieken JH, de Wilde PC, Balvers MG, Adema GJ, De Mulder PH (2005) Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor. Clin Cancer Res 11:1899-1909
33. Michelson AM, Lacour F, Lacour J (1985) Polyadenylic.polyuridylic acid in the cotreatment of cancer. Proc Soc Exp Biol Med 179:1-8
34. Salazar AM, Levy HB, Ondra S, Kende M, Scherokman B, Brown D, Mena H, Martin N, Schwab K, Donovan D, Dougherty D, Pulliam M, Ippolito M, Graves M, Brown H, Ommaya A (1996) Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery 38:1096-1103; discussion 1103-4
35. Ewel CH, Urba WJ, Kopp WC, Smith JW d, Steis RG, Rossio JL, Longo DL, Jones MJ, Alvord WG, Pinsky CM et al (1992) Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects. Cancer Res 52:3005-3010
36. Hovanessian AG, Youn JK, Buffet-Janvresse C, Riviere Y, Michelson M, Lacour J, Lacour F (1985) Enhancement of natural killer cell activity and 2-5A synthetase in operable breast cancer patients treated with polyadenylic; polyuridylic acid. Cancer 55:357-362
37. Tahara H, Lotze MT (1995) Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther 2:96-106
38. Avraham R, Schwartz Y, Rosenne E, Melamed R, Ben-Eliyahu S (2004) IL-12-based immunotherapy reduces post-surgery immunosuppression and metastasis, and increases survival from experimental leukemia. Abstract
39. Slavin S, Ackerstein A, Weiss L, Nagler A, Or R, Naparstek E (1992) Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. Cancer Invest 10:221-227
40. Weiss L, Reich S, Mandelboim O, Slavin S (2004) Murine B-cell leukemia lymphoma (BCL1) cells as a target for NK cell-mediated immunotherapy. Bone Marrow Transplant 33:1137-1141
41. Melamed R, Rosenne E, Shakhar K, Schwartz Y, Abudarham N, Ben-Eliyahu S (2005) Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a beta-adrenergic antagonist and a prostaglandin synthesis inhibitor. Brain Behav Immun 19:114-126
42. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA (2002) Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 100:1935-1947
43. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097-2100
44. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, Moretta A (2002) Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 62:6178-6186
45. Fauriat C, Marcenaro E, Sivori S, Rey J, Gastaut JA, Moretta A, Olive D, Costello RT (2003) Natural killer cell-triggering receptors in patients with acute leukaemia. Leuk Lymphoma 44:1683-1689
46. Yokoyama S, Staunton D, Fisher R, Amiot M, Fortin JJ, Thorley-Lawson DA (1991) Expression of the Blast-1 activation/adhesion molecule and its identification as CD48. J Immunol 146:2192-2000